Closing of First Tranche of $41.8 Million Private Placement of Equity Term Loan Restructured Providing Up to Two Years of Interest Only and Extended Maturity Date to May 2022 Data Requirements Defined to Reinitiate Multiple Ascending Dose and Chronic Dose Studies with RGLS4326 Appointment of Cris
LA JOLLA, Calif. , July 30, 2019 /PRNewswire/ -- Regulus Therapeutics Inc . (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs, today announced the appointment of Cris Calsada as its new Chief Financial Officer effective
Data Requirements Defined To Reinitiate Multiple Ascending Dose And Chronic Dose Studies With RGLS4326 Single Ascending Dose Studies With RGLS4326 May Be Pursued LA JOLLA, Calif. , July 23, 2019 /PRNewswire/ -- Regulus Therapeutics Inc . (Nasdaq: RGLS), a biopharmaceutical company focused on the
LA JOLLA, Calif. , June 11, 2019 /PRNewswire/ -- Regulus Therapeutics Inc . (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs, today announced Jake Nunn and Simos Simeonidis , Ph.D.
Closing of First Tranche of $41.8 Million Private Placement of Equity Term Loan Restructured Providing Up to Two Years of Interest Only and Extended Maturity Date to May 2022 Engagement with FDA on RGLS4326 Clinical Program Ongoing LA JOLLA, Calif. , May 9, 2019 /PRNewswire/ -- Regulus Therapeutics
LA JOLLA, Calif. , May 7, 2019 /PRNewswire/ -- Regulus Therapeutics Inc . (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs, today announced the closing of the first tranche of its previously announced private placement
Term Loan Amended to Provide Up to Two Years of Interest Only Payments and Extension of Maturity Date to May 2022 LA JOLLA, Calif. , May 6, 2019 /PRNewswire/ -- Regulus Therapeutics Inc . (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines
Up to $41.8 Million in Gross Proceeds to be Funded in Two Tranches LA JOLLA, Calif. , May 6, 2019 /PRNewswire/ -- Regulus Therapeutics Inc . (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs, today announced that it has
Favorable Pharmacological Properties Exhibited in Preclinical Models of NASH LA JOLLA, Calif. , April 8, 2019 /PRNewswire/ -- Regulus Therapeutics Inc . (NASDAQ: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs, today announced
LA JOLLA, Calif. , March 18, 2019 /PRNewswire/ -- Regulus Therapeutics Inc . (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs, today reported financial results for the fourth quarter and year ended December 31, 2018
